Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Building on the success of osimertinib: achieving CNS exposure in oncology drug discovery.

Colclough N, Chen K, Johnström P, Fridén M, McGinnity DF.

Drug Discov Today. 2019 May;24(5):1067-1073. doi: 10.1016/j.drudis.2019.01.015. Epub 2019 Jan 30.

PMID:
30710641
2.

Mass Spectrometry Imaging in Oncology Drug Discovery.

Goodwin RJ, Bunch J, McGinnity DF.

Adv Cancer Res. 2017;134:133-171. doi: 10.1016/bs.acr.2016.11.005. Epub 2017 Jan 10. Review.

PMID:
28110649
3.

Application of in silico, in vitro and preclinical pharmacokinetic data for the effective and efficient prediction of human pharmacokinetics.

Grime KH, Barton P, McGinnity DF.

Mol Pharm. 2013 Apr 1;10(4):1191-206. doi: 10.1021/mp300476z. Epub 2013 Jan 29.

PMID:
23253040
4.

Prediction of human renal clearance from preclinical species for a diverse set of drugs that exhibit both active secretion and net reabsorption.

Paine SW, Ménochet K, Denton R, McGinnity DF, Riley RJ.

Drug Metab Dispos. 2011 Jun;39(6):1008-13. doi: 10.1124/dmd.110.037267. Epub 2011 Feb 28.

PMID:
21357702
5.

Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cells.

McGinnity DF, Zhang G, Kenny JR, Hamilton GA, Otmani S, Stams KR, Haney S, Brassil P, Stresser DM, Riley RJ.

Drug Metab Dispos. 2009 Jun;37(6):1259-68. doi: 10.1124/dmd.109.026526. Epub 2009 Mar 23.

PMID:
19307295
6.
7.

Integrated in vitro analysis for the in vivo prediction of cytochrome P450-mediated drug-drug interactions.

McGinnity DF, Waters NJ, Tucker J, Riley RJ.

Drug Metab Dispos. 2008 Jun;36(6):1126-34. doi: 10.1124/dmd.108.020446. Epub 2008 Mar 20.

PMID:
18356267
8.

From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis.

Springthorpe B, Bailey A, Barton P, Birkinshaw TN, Bonnert RV, Brown RC, Chapman D, Dixon J, Guile SD, Humphries RG, Hunt SF, Ince F, Ingall AH, Kirk IP, Leeson PD, Leff P, Lewis RJ, Martin BP, McGinnity DF, Mortimore MP, Paine SW, Pairaudeau G, Patel A, Rigby AJ, Riley RJ, Teobald BJ, Tomlinson W, Webborn PJ, Willis PA.

Bioorg Med Chem Lett. 2007 Nov 1;17(21):6013-8. Epub 2007 Aug 19.

PMID:
17827008
9.

Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs.

McGinnity DF, Collington J, Austin RP, Riley RJ.

Curr Drug Metab. 2007 Jun;8(5):463-79.

PMID:
17584017
10.

The pivotal role of hepatocytes in drug discovery.

Soars MG, McGinnity DF, Grime K, Riley RJ.

Chem Biol Interact. 2007 May 20;168(1):2-15. Epub 2006 Nov 18. Review.

PMID:
17208208
11.

Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes.

McGinnity DF, Berry AJ, Kenny JR, Grime K, Riley RJ.

Drug Metab Dispos. 2006 Aug;34(8):1291-300. Epub 2006 May 5.

PMID:
16679385
12.

Prediction of CYP2C9-mediated drug-drug interactions: a comparison using data from recombinant enzymes and human hepatocytes.

McGinnity DF, Tucker J, Trigg S, Riley RJ.

Drug Metab Dispos. 2005 Nov;33(11):1700-7. Epub 2005 Aug 4.

PMID:
16081671
13.

A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes.

Riley RJ, McGinnity DF, Austin RP.

Drug Metab Dispos. 2005 Sep;33(9):1304-11. Epub 2005 Jun 2.

PMID:
15932954
14.

Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance.

McGinnity DF, Soars MG, Urbanowicz RA, Riley RJ.

Drug Metab Dispos. 2004 Nov;32(11):1247-53. Epub 2004 Jul 30.

PMID:
15286053
15.

Predicting drug pharmacokinetics in humans from in vitro metabolism studies.

McGinnity DF, Riley RJ.

Biochem Soc Trans. 2001 May;29(Pt 2):135-9.

PMID:
11356141
16.

Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s.

McGinnity DF, Parker AJ, Soars M, Riley RJ.

Drug Metab Dispos. 2000 Nov;28(11):1327-34.

PMID:
11038161
17.

Rapid characterization of the major drug-metabolizing human hepatic cytochrome P-450 enzymes expressed in Escherichia coli.

McGinnity DF, Griffin SJ, Moody GC, Voice M, Hanlon S, Friedberg T, Riley RJ.

Drug Metab Dispos. 1999 Sep;27(9):1017-23.

PMID:
10460801
18.
19.

Multiple activated oxygen species in P450 catalysis: contributions To specificity in drug metabolism.

Coon MJ, Vaz AD, McGinnity DF, Peng HM.

Drug Metab Dispos. 1998 Dec;26(12):1190-3. Review.

PMID:
9860926
20.
21.

Structural characterization of Paracoccus denitrificans cytochrome c peroxidase and assignment of the low and high potential heme sites.

Hu W, Van Driessche G, Devreese B, Goodhew CF, McGinnity DF, Saunders N, Fulop V, Pettigrew GW, Van Beeumen JJ.

Biochemistry. 1997 Jul 1;36(26):7958-66.

PMID:
9201942
22.

A single histidine is required for activity of cytochrome c peroxidase from Paracoccus denitrificans.

McGinnity DF, Devreese B, Prazeres S, Van Beeumen J, Moura I, Moura JJ, Pettigrew GW.

J Biol Chem. 1996 May 10;271(19):11126-33.

23.

The affinity and specificity of Ca(2+)-binding sites of cytochrome-c peroxidase from Paracoccus denitrificans.

Gilmour R, Prazeres S, McGinnity DF, Goodhew CF, Moura JJ, Moura I, Pettigrew GW.

Eur J Biochem. 1995 Dec 15;234(3):878-86.

Supplemental Content

Loading ...
Support Center